^
    8d
    A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=400, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • etoposide IV • AiRuiLi (adebrelimab)
    11d
    ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, AgonOx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
    |
    AGX-148
    13d
    NWRD06 DNA Plasmid for HCC After Curative Resection. (clinicaltrials.gov)
    P2, N=30, Recruiting, Newish Technology (Beijing) Co., Ltd.
    New P2 trial
    |
    GPC3 (Glypican 3)
    15d
    MAST: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Imugene Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • VAXinia (CF33-hNIS)
    26d
    NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. (PubMed, J Immunother Cancer)
    These findings were validated in an immunocompetent B-cell lymphoma mouse model, where NX-1607 consistently upregulated PLCγ1 and ERK phosphorylation. Together, this work delineates a PLCγ1-MAPK/ERK axis through which Cbl-b inhibition unleashes T cell activation, providing critical insight for the development of NX-1607 based immunotherapy.
    Journal • IO biomarker
    |
    CD69 (CD69 Molecule)
    |
    NX-1607
    1m
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations (clinicaltrials.gov)
    P1, N=24, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | Trial completion date: Feb 2026 --> Jan 2028 | Trial primary completion date: Feb 2026 --> Jan 2028
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    1m
    A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Imugene Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Blincyto (blinatumomab) • hydroxyurea • VAXinia (CF33-hNIS) • onCARlytics (CF33-CD19)
    1m
    GEN001-201: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Completed, Genome & Company | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • GEN-001
    1m
    KEYNOTE-D86: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Genome & Company | Recruiting --> Terminated | N=148 --> 10; Sponsor decision
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • GEN-001
    2ms
    A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=400, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial
    |
    cisplatin • carboplatin • etoposide IV • AiRuiLi (adebrelimab)
    2ms
    Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (clinicaltrials.gov)
    P1, N=16, Completed, Providence Health & Services | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cyclophosphamide • citoplurikin (IRX-2) • omeprazole
    2ms
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)